Navigation Links
OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
Date:6/3/2010

BOTHELL, WA and VANCOUVER, June 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, OncoGenex's President and Chief Executive Officer, will present at the 9th Annual Needham Healthcare Conference on June 10 at 10:40 a.m. ET at the New York Palace Hotel in New York City.

A live webcast will be available through the Investor Relations page of the OncoGenex Web site at http://ir.oncogenex.com. A webcast replay will be available approximately two hours after the call and will be archived for 90 days.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva have entered a global collaboration and license agreement to develop and commercialize OncoGenex's lead drug candidate, OGX-011. The companies expect to initiate two Phase III trials in castrate resistant prostate cancer in 2010, and a third Phase III trial in non-small cell lung cancer in early 2011. OGX-427 is in Phase I clinical development; SN2310 has completed a Phase I clinical trial; and CSP-9
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. OncoGenex Reports First Quarter Financial Results
2. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
3. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
4. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
5. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
6. OncoGenex Reports Third Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
8. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
9. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
10. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
11. OncoGenex Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Vycom announces the addition of Thermax ... meet Factory Mutual (FM) 4910 fire propagation and smoke ... benches, process tools, fume hoods, furniture and cabinetry. These ... semiconductor wafers used in electronic chip manufacturing. , ... with excellent workability and superior aesthetics. It is available ...
(Date:7/30/2014)... , July 30, 2014 Researchers often ... interrogate biology, but such devices can do much ... As such, researchers have looked to patterned ... vitro metabolic engineering to characterize – and ... New devices are envisioned to recreate animal and ...
(Date:7/30/2014)... NCERC at Southern Illinois University Edwardsville ... on corn stover pretreatment methods at a U.S. ... D.C. , “Arun’s selection for presentation at ... to the success of our postdoctoral fellowship program,” ... foresight and vision of SIUE and the Illinois ...
(Date:7/30/2014)... Immunology Summit-2014 will ... Investigators, scientists in the field, which includes prominent ... Case Western Reserve University School of Medicine, USA, ... “The effects of recombinant human IL-6 and ... Arya Biragyn, a Senior investigator at National Institute ...
Breaking Biology Technology:Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... FRANCISCO, Calif., Jan. 4 Cerimon,Pharmaceuticals, Inc. announced ... Counsel, a newly established position, and Vice President ... global life sciences,executive and corporate attorney with broad ... in the US and,Europe. In the business development ...
... efficacy in treatment of multi-drug ... resistant infections -, ... "Company"), a biopharmaceutical company focused on the,development of novel antibiotics for ... patients in two,separate Phase 2 clinical trials. The studies will evaluate ...
... and biotechnology ... expertise, BOSTON, Jan. 3 Observant LLC has ... for research excellence,and a commitment to client service. John ... firm as Vice President. Dr. Hartman,s,research has focused on ...
Cached Biology Technology:Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing 2Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 2Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 3Observant LLC Expands Senior Management Team 2
(Date:7/30/2014)... July 30, 2014 NexID Biometrics ... liveness detection solutions for the biometric authentication industry, ... consortium revolutionizing online authentication with standards for strong ... , "The decision to join FIDO Alliance stems ... pervasive in use. We believe the FIDO Alliance ...
(Date:7/30/2014)... Scientists are searching through a massive collection of 20-million-year-old ... years ago, and the effort is yielding fresh insights ... , When the collection is fully curated, a task ... largest unbiased Dominican amber collection in the world, the ... thus far is that of a pygmy locust, a ...
(Date:7/30/2014)... in cancer treatment has been shown to relieve ... for neural transmission between the peripheral and central ... Institute of Radiation Medicine, Chinese Academy of Medical ... into rat dorsal root ganglia (DRG) to provide ... radioactivity (0, 14.8, 29.6 MBq) were implanted separately ...
Breaking Biology News(10 mins):NexID Biometrics Joins the FIDO Alliance 2Decades-old amber collection offers new views of a lost world 2
... 21 February 2011 Elsevier, a world-leading publisher ... services, and TAIR - The Arabidopsis Information Resource, ... elements of scientific research. All articles on Elsevier,s ... genes and use AGI codes (e.g. AT4G32520) will ...
... Researchers at Albert Einstein College of Medicine ... to protect against an increasingly common and particularly deadly form ... tested in an animal model, are reported in a paper ... Pneumococcal pneumonia can occur when the lungs are ...
... heart diseases affect approximately one in 100 patients, making ... number-one cause of pediatric deaths. Now a new ... cardiac muscle damage in a mouse model of the congenital ... treatment for this rare condition, but also demonstrates the importance ...
Cached Biology News:Vaccine made with synthetic gene protects against deadly pneumonia 2Vaccine made with synthetic gene protects against deadly pneumonia 3Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome 2Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome 3
...
Experion spin filters are used to filter the gel matrix and gel stain solution prior to use with the Experion automated electrophoresis system. Supplied as 10 spin filters....
...
... to PRKAR2 cAMP is a signaling ... functions. cAMP exerts its effects by activating ... the signal through phosphorylation of different target ... a tetramer composed of two regulatory and ...
Biology Products: